Self-administered Biologics Market to Reach USD 147.48 Billion by 2034 | Say Statifacts.

According to Statifacts, the global self-administered biologics market size was valued at USD 94.06 billion in 2024 and is expected to reach USD 147.48 billion by 2034, growing at a CAGR of 4.6% from 2024 to 2034.

View Detailed Dataset (Price: USD 1550) ; https://www.statifacts.com/outlook/self-administered-biologics-market

There has been an increase in diagnosis of chronic diseases, including cases of autoimmune disorders, cancer, and genetic diseases. Biologics is a major part of the treatment regime for these ailments. Many small-molecule biologics are administered through subcutaneous routes. The rise in subcutaneous formulation of numerous biologics has driven the self-administered biologics market.

Subcutaneous is a safe option and does not need extensive skills in locating the vein as in the case of IV formulations. This has paved the way for the adoption of self-administered biologics formulations. The advancement in self-administrable devices such as prefilled syringes, autoinjectors, wearable injectors, drug reconstitution delivery systems, and pen injectors, etc. have catalyzed the growth of the market.

Patients can administer subcutaneous formulations to themselves without the need for any elaborate pre-use training. Subcutaneous delivery is preferred over oral routes because subcutaneous delivery inherently provides better bioavailability and higher absorption rates with large molecules. Preference studies have shown a great affinity towards self-administration because of the flexibility and lower healthcare cost compared to IV doses.

Also, the incorporation of technologies like hyaluronidase increases absorption rates. COVID-19 fueled an interest in more decentralized healthcare solutions that could be more patient-centric and at home. As the costs of healthcare rise, and access becomes more of an issue, self-administered biologics afford such opportunities, a reduction of the number of clinic visits vs intravenous therapies.

While the market is experiencing growth there persist certain challenges. Certain biologics formulations having high viscosity and other technical problems are not administrable through the current self-administration devices.

However additional investments have been made in developing self-administration devices, for example, electromechanical auto-injectors that include variable-speed control for administering drugs and are capable of keeping patient electronic logs, amongst other features.

Reusable high-viscosity biologics delivery systems are developed that address challenges in drug administration and at the same time promote sustainability.

The culmination of the above factors points towards a promising future for the self-administered biologics market in response to the exploding demand of patients for the most convenient, cost-effective, and improved treatment experience.

𝐔𝐧𝐥𝐨𝐜𝐤 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐛𝐲 𝐞𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 FREE 𝐬𝐚𝐦𝐩𝐥𝐞 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤; https://www.statifacts.com/download-product/6483

Rise in the Approval of Subcutaneously Delivered Biologics Drive Self-Administered Biologics Market

Subcutaneous administration is easier and more convenient for self-injection, especially in the management of chronic conditions. Many drugs, such as benralizumab, dupilumab, mepolizumab, and omalizumab, are now available in pre-filled pens and syringes; quite easy for patients to administer medications on their own and without extensive training and healthcare support.

This route of administration combines the advantages of increased bioavailability and absorption rates compared with the oral routes, specifically for large molecules that are difficult to absorb in the gastrointestinal tract.

Growing acceptance of subcutaneous biologics is also supported by patient preference studies, which demonstrate a high trend in support of self-administration because of flexibility and reduced costs to healthcare. Moreover, there is the integration of technologies like hyaluronidase that increase the absorption rates of these medications.

With an increasing number of biologics getting regulatory approval for subcutaneous delivery, this market for self-administered biologics will increase further to the benefit of patients and healthcare systems. Over the past few years, the approval of subcutaneously delivered biologics has increased as a function of new drug formulation and delivery technologies.

Regulatory bodies seem to increasingly recognize patient preference data in their assessment, which allows more subcutaneous options to be approved. Finally, the COVID-19 pandemic exacerbated this trend by increasing interest in decentralized health solutions that empower patients to treat from home.

Self-administered Biologics Market Companies:

• Novo Nordisk
• Eli Lilly
• Johnson & Johnson
• Pfizer
• Roche
• AbbVie
• Bristol-Myers Squibb
• GlaxoSmithKline
• Novartis
• Sanofi
• Takeda Pharmaceutical
• AstraZeneca
• Bayer

Self-administered Biologics Market Segmentation:

By Indication

• Diabetes
• Rheumatoid Arthritis
• Anaphylaxis
• Others

By Product

• Prefilled Syringes
• Autoinjectors
• Wearable Injectors
• Drug Reconstitution Delivery Systems
• Pen Injectors

By Mode of Delivery

• Subcutaneous
• Intramuscular
• Transdermal

By End User

• Homecare Settings
• Hospitals/Clinics

By Brand

• Branded Biologics
• Biosimilars

By Technology

• Conventional Devices
• Smart Devices

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors

• Provision of market value (USD Billion) data for each segment and sub-segment

• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

• Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come

• 6-month post-sales analyst support

Buy this Databook@ (Price: USD 1550); https://www.statifacts.com/order-report/6483

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:
Ballindamm 22, 20095 Hamburg, Germany
Email: sales@statifacts.com
Europe : +44 7383 092 044

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and customer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG.

Visit Our Sitemap: https://www.statifacts.com/outlook/sitemap.xml

This release was published on openPR.